Edition:
India

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

7.47USD
1:30am IST
Change (% chg)

$0.06 (+0.81%)
Prev Close
$7.41
Open
$7.43
Day's High
$7.55
Day's Low
$7.21
Volume
615,901
Avg. Vol
615,409
52-wk High
$7.55
52-wk Low
$2.71

Latest Key Developments (Source: Significant Developments)

Cerus Corporation Announces FDA Pma Supplement Submission For Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
Tuesday, 26 May 2020 

Cerus Corp ::CERUS CORPORATION ANNOUNCES FDA PMA SUPPLEMENT SUBMISSION FOR PATHOGEN-REDUCED CRYOPRECIPITATED FIBRINOGEN COMPLEX.CERUS CORP - PMA-S INCLUDES SUBMISSION FOR PATHOGEN-REDUCED CRYOPRECIPITATE-POOR PLASMA.  Full Article

Cerus Corporation Announces First Quarter 2020 Results
Wednesday, 6 May 2020 

May 5 (Reuters) - Cerus Corp ::ORATION ANNOUNCES FIRST QUARTER 2020 RESULTS.Q1 LOSS PER SHARE $0.10.Q1 REVENUE $24.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $23.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.SAYS REAFFIRMING 2020 FULL YEAR PRODUCT REVENUE GUIDANCE RANGE OF $89 MILLION TO $93 MILLION.  Full Article

Cerus Corporation Announces FDA Approval For Intercept Blood System
Monday, 4 May 2020 

May 4 (Reuters) - Cerus Corp ::CERUS CORPORATION ANNOUNCES FDA APPROVAL FOR INTERCEPT BLOOD SYSTEM FOR PLASMA WITH ALTERNATE PLASTIC DISPOSABLE KITS.  Full Article

Cerus Announces Expansion Of BARDA Funding To Support Development Of Intercept Blood System For RBCs
Tuesday, 21 Apr 2020 

April 20 (Reuters) - Cerus Corp ::CERUS CORPORATION ANNOUNCES EXPANSION OF BARDA FUNDING TO SUPPORT DEVELOPMENT OF INTERCEPT BLOOD SYSTEM FOR RED BLOOD CELLS.CERUS CORP - AMENDMENT PROVIDES AN ADDITIONAL $14 MILLION IN AVAILABLE FUNDING.CERUS CORP - $14 MILLION CONTRACT AMENDMENT INCLUDES ADDITIONAL FUNDING FOR REDES.CERUS CORP - AMENDMENT INCREASING TOTAL POTENTIAL VALUE OF CONTRACT TO $214 MILLION.CERUS CORP - CONTRACT EXPANSION PROVIDES FUNDING TO FURTHER EVALUATE EFFICACY OF INTERCEPT BLOOD SYSTEM.CERUS CORP - MANY PARTICIPATING CLINICAL TRIAL HOSPITAL SITES HAVE TEMPORARILY SUSPENDED ENROLLMENT IN REDES AND RECEPI STUDIES.  Full Article

Cerus Posts Quarterly Loss Per Share Of $0.12
Friday, 21 Feb 2020 

Feb 20 (Reuters) - Cerus Corp ::ORATION ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.12.Q4 REVENUE $26.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $25.3 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.PROVIDED 2020 ANNUAL PRODUCT REVENUE GUIDANCE OF $89 MILLION TO $93 MILLION.ANTICIPATE MOMENTUM CO EXPERIENCED PAST YEAR WILL CONTINUE INTO 2020.FY2020 REVENUE VIEW $110.8 MILLION -- REFINITIV IBES DATA.  Full Article

Cerus Reports Q3 Loss Per Share Of $0.13
Thursday, 31 Oct 2019 

Oct 30 (Reuters) - Cerus Corp ::ANNOUNCES THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.13.Q3 REVENUE $22.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $22.8 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.REAFFIRMS ITS 2019 PRODUCT REVENUE GUIDANCE.2019 PRODUCT REVENUE GUIDANCE REAFFIRMED AT $72 MILLION TO $75 MILLION.  Full Article

Cerus Corp Reports Q2 Loss Per Share $0.13
Friday, 2 Aug 2019 

Aug 1 (Reuters) - Cerus Corp ::CERUS CORPORATION ANNOUNCES RECORD SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.13.Q2 REVENUE $22.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $22.3 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.RAISING 2019 FULL YEAR PRODUCT REVENUE GUIDANCE TO A RANGE OF $72 MILLION TO $75 MILLION.  Full Article

Cerus Corporation Q1 Loss Per Share $0.14
Wednesday, 8 May 2019 

May 7 (Reuters) - Cerus Corp ::ANNOUNCES RECORD FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $0.14.Q1 REVENUE $22 MILLION VERSUS REFINITIV IBES ESTIMATE OF $20.9 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.2019 FULL YEAR PRODUCT REVENUE GUIDANCE BEING RAISED TO RANGE OF $71 MILLION TO $74 MILLION FROM $70 MILLION TO $73 MILLION.QTRLY GOVERNMENT CONTRACT REVENUE OF $4.5 MILLION.  Full Article

Cerus Reports Q4 Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Cerus Corp ::ORATION ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 LOSS PER SHARE $0.12.Q4 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.2019 ANNUAL PRODUCT REVENUE GUIDANCE OF $70 MILLION TO $73 MILLION.QTRLY PRODUCT REVENUE $16.5 MILLION VERSUS $16.2 MILLION.  Full Article

BRIEF-Cerus Corp Reports Successful Inactivation Of Sars-Cov-2 With The Intercept Blood System For Plasma

* CERUS CORPORATION REPORTS SUCCESSFUL INACTIVATION OF SARS-COV-2 WITH THE INTERCEPT BLOOD SYSTEM FOR PLASMA